Dragonfly Therapeutics, Inc. Announces Clinical Collaboration to Evaluate DF9001, an EGFR targeting TriNKET®, in Combination with KEYTRUDA® in Patients with Solid Tumors

Dragonfly Therapeutics, Inc. Massachusetts

View original content:https://www.prnewswire.co.uk/news-releases/dragonfly-therapeutics-inc-announces-clinical-collaboration-to-evaluate-df9001-an-egfr-targeting-trinket-in-combination-with-keytruda-pembrolizumab-in-patients-with-solid-tumors-302150800.html